TradingView
cryptr0t
Dec 4, 2018 6:24 PM

AIMT has long term potential. 做多

描述

AIMT has just hit the all time 52 week low today. They've recently published good news on their AR101 clinical results and with no life threatening adverse results. There is a high percentage of probability the BLA will be granted Fast track designation by the FDA, based on recent data results. The question is not if, but when this gem of a security will take-off.

评论

On January 4th, AIMT announced a 170MM loan agreement with KKR to fund the commercialization of AR101 pipeline. Quick recap, December was rough terrain for the entire market. What really impressed me is the resilience and performance we are observing out of AIMT under such adverse conditions.

On a more concrete analysis, the following is a personal analysis and is not intended for investment purposes. "Based on a U.S. statistical population reported in January 7th, 2019 accrues a total population of 327.9MM. A market analysis for peanut allergies is estimated at an annual rate of 16,396,767 same as 5% of overall population.

For those that may be unaware, we are talking about an untapped medical condition which has a history resulting in life threatening reactions that send adults and children to the E.R. every year. Projections for annual U.S. market of AR101 falls in the range of 1.6B which will compound on annual basis."
评论
cryptr0t
Study results published yesterday confirm AR101 is a high value proposition to peanut food allergies. These results have pushed 16% upward movement. Long term analysis remains with a bullish prognosis. Some updates, the security market was clobbered this month (Dec 2018), analyst have compared it to the worst December since the great depression due to many geo-political issues, rising inflation, etc. It's been rough sails for most market segments as investors are wary on the outlook and have reduced there positions due to adverse speculations. However, AIMT has managed to batter the storms and is on the right track to success. 2019 is a bright future for AIMT.

Reference: seekingalpha.com/news/3418224-aimmune-launches-late-stage-study-ar101-young-children-shares-3-percent
cryptr0t
Fundamentals indicates AIMT is approaching oversold territory if it tests the $22.50 range.
更多